Novartis on Friday posted quarterly adjusted net income well above analyst estimates on higher drug revenues. Fourth-quarter ...

Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its ...

Swiss drug major Novartis AG (NVS) reported Friday that its fourth-quarter net income plunged to $2.82 billion from last year's $8.48 ...

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

SALES FORECAST: Novartis's sales are forecast at $12.78 billion, according to analysts' estimates compiled by Visible Alpha. This compares with $11.42 billion the year before. Shares rose 5.1% over ...

In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

In Novartis Pharms. Corp. v. Torrent Pharma Inc., the U. S. Court of Appeals for the Federal Circuit shut down efforts to market a generic version of the heart disease drug ENTRESTO which is sold ...